The percentages of total ether GLs and plasmalogens were similar between the two groups, while that of the rest of the ether GLs, mainly attributed to the platelet-activating factor (PAF), was significantly higher in MASLD compared to controls (Table 3). Here, PCLAF is linked to metabolic dysfunction-associated steatotic liver disease.